Notably, recent concepts depicting the therapeutic role of IL-1β in endometriosis have emerged (52), raising the question of which one is the better treatment strategy, targeting IL-1β or NLRP3, or even a combined regimen. This evidence concerns the gene IL1B and endometriosis.